Gene Fusion Panel

gene_testing

In recent years an increasing number of gene fusions have been identified in solid tumors, many of them involving kinases that are targetable with specific therapies. The GeneTrails® Solid Tumor Fusion Gene panel is designed to be a comprehensive panel that targets 20 clinically relevant gene fusions. The panel works on FFPE tissue and is performed using next-generation sequencing of tumor RNA. It is useful for finding clinically actionable fusions that are not routinely screened by FISH. Control genes are included on the panel to assess specimen adequacy.

This panel uses a combination of multiplexed amplification and next-generation sequencing to identify ALK gene fusions with up to 19 different partners, as well as fusions involving ROS1, RET, and all members of the FGFR and NTRK gene families. Sequencing is performed on cDNA from FFPE RNA and requires very little (20 ng) input material. The panel demonstrates excellent sensitivity (>95%) and specificity (100%). Positive results are confirmed by standard FISH before reporting.

GeneTrails® Hematologic Malignancies 76 Gene Panel

gene_testing2Screening for mutations in oncogenes and tumor suppressor genes is increasingly important in delivering personalized cancer care. The GeneTrails® Hematologic Malignancies 76 Gene Panel delivers information on predictive and prognostic mutations commonly involved in hematolymphoid malignancies and precursor lesions, including acute myelogenous and lymphoid leukemias, myelodysplasias, myeloproliferative disorders, and lymphomas. Some mutations detected on this panel may directly inform targeted or non-targeted treatment options. This panel covers nearly all of the mutation sites in the 76 genes listed below and is supplemented by Sanger sequencing. The panel has a sensitivity of ~5 % mutant allele with strict next generation sequencing quality control parameters.

The GeneTrails® Hematologic Malignancies 76 Gene Panel is performed on DNA extracted from blood, bone marrow aspirate or biopsy, or formalin-fixed, paraffin-embedded (FFPE) bone marrow. The assay uses next-generation, semiconductor-based massively parallel sequencing (Ion Torrent PGM platform).

Innovations in Testing
View All Tests

The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials.

Learn More